Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant 177Lu-PSMA-I&T before radical prostatectomy for node-positive hormone-sensitive prostate cancer
2020-004991-16Phase 2Active
- Start
- Jun 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa). Primary endpoint: Surgical feasibility and safety. Started Jun 2022; status: active.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-004991-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004991-16.